ROS1 fusion mutations and targeted drugs

The three major cancers of human beings are lung cancer, stomach cancer, and liver cancer. Incidence of lung cancer.

DAO is relatively high within lung cancer due to lung dysfunction.

In the early stage of lung cancer, it can be carried out by surgery, and there is a chance that if it develops to an advanced stage, the hope is very slim, it can only be said to prolong his life cycle, and it is necessary to consult the attending physician.

Lung cancer is mainly divided into non-small cell lung cancer (NSCLC) and small cell lung BAI cancer (SCLC), and about 85% of patients have non-DU small cell lung cancer (NSCLC), including lung adenocarcinoma, DAO lung squamous cell carcinoma, and large cell lung cancer.

1. Non-small cell lung cancer (NSCLC).

1. Lung adenocarcinoma.

The more common mutated genes are EGFR, ALK, CMET, ROS1, HER2, KRAS, etc., which are also the cancer types with the most targeted drugs at present.

2. Squamous cell carcinoma of the lung.

Common gene mutations include FGFR1, STK11, SOX, PIK3CA, DDR2, PDGFRA, MDM2, etc.

3. Large cell lung cancer.

At present, there is no particularly effective targeted drug for large cell lung cancer, and it has been reported in the literature that EGFR mutations are effective for gefitinib, and cross-indication drug detection of gene mutations can be considered.

2. Small cell lung cancer

Features of small cell lung cancer:

Small cell lung cancer accounts for about 15% of the total number of lung cancers, with a high degree of malignancy, ** limited measures, and there are currently no approved targeted drugs, which initially have a good response to chemotherapy and radiotherapy.

Which gene mutation, if it is an EGFR gene mutation, EGFR-TKI targeted drugs can be used; If it is an ALK fusion mutation, an ALK inhibitor can be used (ALK fusion mutation is a ** mutation, and alternating ALK inhibitors can achieve 5 to 10 years of survival in the later stage). There are other mutations that may not be targeted drugs.

Recent analyses from clinical studies in patients with RoS1-mutated NSCLC suggest that in patients with ROS1-positive advanced metastatic NSCLC, median progression-free survival (PFS) after receiving entrectinib** can range from 1 year to more than two years, regardless of brain metastases. According to the data from Hong Kong and An's Health, entrectinib is a novel, orally available, central nervous system active tyrosine kinase inhibitor (TKI) targeting solid tumors harboring fusion mutations in NTRK1 2 3 (encoding TRKA TRKB TRKC), ROS1 and ALK genes. Entrectinib crosses the blood-brain barrier and does not have undesirable off-target activity.

Entrectinib works by an oral tyrosine kinase inhibitor with central nervous system activity, primarily targeting tumors with mutations in NTRK1 2 3, ROS1 or ALK genes. Entrectinib is currently the only clinically proven tyrosine kinase inhibitor with active targeting primary and metastatic central nervous system cancers and no adverse off-target effects.

The early symptoms of lung cancer are mainly cough, sputum production, and occasionally blood in the sputum. A small number of patients will have weight loss and joint pain, but the vast majority of lung cancer is asymptomatic in the early stage, and lung cancer is mainly detected by low-dose lung CT screening in high-risk patients and lung masses. Once a lung mass is found, a needle biopsy of the lung mass is needed to determine whether it is lung cancer.

Pulmonary examination should also be enhanced to rule out concomitant lymph node metastases. Only when the lung tumor is relatively small, less than 3 cm, and there is no lymph node metastasis, can it be called early lung cancer.

Prevention of lung cancer should be done in the following ways:

1. Smoking can lead to an increase in the incidence of lung cancer, so you should quit smoking and prevent inhaling second-hand smoke;

2. Kitchen fumes can lead to an increase in the incidence of lung cancer, and fumes will be produced during cooking, so you can open the windows for ventilation to minimize the harm of fumes;

3. Healthy diet, not suitable for fried food, as well as barbecue food;

4. Patients engaged in high-risk occupations should take necessary precautions;

5. When the air pollution is heavy, you should reduce going out, and you should do a good job of protection when you go out;

6. Live a regular life and keep a happy mood.

Due to the serious environmental pollution in today's society, the continuous decline of air quality, coupled with people's usual bad habits, the incidence of lung cancer is getting higher and higher. Many people lose hope after being diagnosed with lung cancer. Because in the consciousness of most people, cancer is a "terminal disease", and having cancer is equivalent to a death sentence.

So, is this really the case with cancer? Is there really no way to do lung cancer? With the continuous development of science and technology, human experience in lung cancer has gradually become richer.

1. Surgery: At present, most of the advocates for lung cancer are to maximize the resection of lung cancer and preserve lung function to the greatest extent, and in recent years, more advocates are lobectomy and surgery combined with a variety of methods.

1. The commonly used methods of lung resection are: 1) total lung resection; 2) lobectomy; 3) sleeve lobectomy 4) segment resection; 5) Tumor resection.

2. Normative lobectomy.

3. Cryosurgery**.

2. Radiation**:

1. Radiotherapy for small cell lung cancer (SCLC) is often used in conjunction with chemotherapy.

2. Radiotherapy for non-small cell (NSCLC) lung cancer includes preoperative radiotherapy, postoperative radiotherapy, ** radiotherapy, cavity brachybratic postloading radiotherapy and interstitial radiotherapy.

The main complications of radiotherapy are: esophageal injury, lung injury, heart injury and myelitis.

3. Chemistry**:

In recent years, chemotherapy has received more and more attention in lung cancer, and chemotherapy for small cell lung cancer and non-small cell lung cancer should be treated differently.

1. Chemotherapy is the main method of small cell lung cancer, mainly including: single-agent chemotherapy, combination chemotherapy and alternating chemotherapy.

2. The efficacy of chemotherapy for non-small cell lung cancer is much lower than that for small cell lung cancer, mainly including: single agent and combination therapy, adjuvant chemotherapy in radiation**.

** Methods for lung cancer include:

1. Internal medicine**: such as chemistry**, targeting**;

2. Surgery: including sexual surgery, palliative surgery, etc.;

3. Radioactivity**;

4. Others: such as traditional Chinese medicine**, intervention** and biology**, etc.

Internal medicine, surgery, and radiotherapy are commonly used in clinical lung cancer, and surgery is the first choice for early lung cancer, and for advanced lung cancer that has metastasized, it is necessary to be comprehensive, and those with gene mutations can consider targeting, and targeted drugs have been developed to the third generation, and the effect is better for patients with advanced lung cancer. Chemotherapy is mostly for advanced lung cancer, especially squamous cell carcinoma. Biological** is a new clinical approach that can improve efficacy and prolong life.

Lung cancer is a malignant tumor of the respiratory tract, if the lung cancer has now metastasized to the bone, then it means that it has reached the advanced stage of cancer, during this time the patient's body is relatively weak, the specific survival time needs to be determined according to the individual's situation, this time can be cooperated with the doctor with targeted drugs for **,

Mutations in the EGFR gene, ALK, ROS1 genes, etc., have been detected.

Hello, patients with advanced non-small cell lung cancer can take Iricor, but the premise is that patients who have done genetic testing and have EGFR mutations, because targeted drugs need to have targets to work, and if there is no target, targeted drugs cannot play an anti-tumor role. In addition, patients with positive genetic testing for ALK fusion or ROS1 fusion may be given crizotinib.

Yes, Irico has significant efficacy on advanced non-small cell lung cancer, but patients must first meet the EGFR gene positive mutation, so it is recommended to do genetic testing first, if the conditions are met, it is recommended to use, compared with radiotherapy and chemotherapy, Erico not only has obvious advantages in prolonging what patients and controlling tumor development, but also has a lower quality of life for patients.